



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|--------------------------|
| Application Number | 10/684,268 |
| Filing Date | October 10, 2003 |
| First Named Inventor | MONTERO-JULIAN, Felix A. |
| Art Unit | 1641 |
| Examiner Name | FOSTER, Christine E. |
| Attorney Docket Number | 2512.0230001/KWM/C-K |

U.S. PATENT DOCUMENTS

| Examiner Initials [*] | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------------------|-----------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| | US1 | 4,048,298 | 09/13/1977 | Niswender | |
| | US2 | 4,120,945 | 10/17/1978 | Gutcho <i>et al.</i> | |
| | US3 | 4,228,237 | 10/14/1980 | Hevey <i>et al.</i> | |
| | US4 | 4,478,946 | 10/23/1984 | Van der Merwe <i>et al.</i> | |
| | US5 | 5,534,416 | 07/09/1996 | Millard <i>et al.</i> | |
| | US6 | 5,583,031 | 12/10/1996 | Stern | |
| | US7 | 5,734,023 | 03/31/1998 | Nag <i>et al.</i> | |
| | US8 | 5,965,532 | 10/12/1999 | Bachovchin | |
| | US9 | 6,037,135 | 03/14/2000 | Kubo <i>et al.</i> | |
| | US10 | 6,355,479 | 03/12/2002 | Webb <i>et al.</i> | |
| | US11 | 6,419,931 | 07/16/2002 | Vitiello <i>et al.</i> | |
| | US12 | 2002/0006903 A1 | 01/17/2002 | Schneck <i>et al.</i> | |
| | US13 | 2003/0044415 A1 | 03/06/2003 | Savage | |
| | US14 | 2003/0191286 A1 | 10/09/2003 | Hildebrand <i>et al.</i> | |
| | US15 | 2003/0044389 A1 | 03/06/2003 | Brown <i>et al.</i> | |
| | US16 | 2004/0072262 A1 | 04/15/2004 | Montero-Julian <i>et al.</i> | |
| | US17 | 2004/0253632 A1 | 12/16/2004 | Rhode <i>et al.</i> | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials [*] | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | FP1 | WO 92/07952 A1 | 05/14/1992 | Immologic Pharma Corp. <i>et al.</i> | | |
| | FP2 | WO 95/04817 A1 | 02/16/1995 | Cytel Corp. | | |
| | FP3 | WO 97/00067 A1 | 01/03/1997 | University of Victoria | | |
| | FP4 | WO 97/004085 A1 | 02/06/1997 | Boehringer Mannheim GmbH | | |
| | FP5 | WO 97/09429 A2 | 03/13/1997 | Corixa Corp. | | |
| | FP6 | WO 98/23690 A1 | 06/04/1998 | Eastman Chemical Co. | | |
| | FP7 | WO 01/90747 A2 | 11/29/2001 | Sunol Molecular Corp. | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO. FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| | | | | Attorney Docket Number | 2512.0230001/KWM/C-K |
| Sheet | 2 | of | 2 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| | FP8 | WO 04/094458 A2 | 11/04/2004 | University of Massachusetts <i>et al.</i> | | |
| | FP9 | WO 05/010026 A2 | 02/03/2005 | Beckman Coulter, Inc. | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

826856v1

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 1 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | NPL1 | BODINIER, M., <i>et al.</i> , "Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding," <i>Nat. Med.</i> 6:707-710, Nature Publishing Company (2000) | |
| | NPL2 | BUUS, S., <i>et al.</i> , "The Relation Between Major Histocompatibility Complex (MHC) Restriction and the Capacity of Ia to Bind Immunogenic Peptides," <i>Science</i> 235:1353-1358, American Association for the Advancement of Science (1987) | |
| | NPL3 | CARBONE, F.R., and BEVAN, M.J., "Chapter 18: Major Histocompatibility Complex Control of T Cell Recognition," in <i>Fundamental Immunology</i> 2 nd Ed., Paul, W.E., ed., Raven Press Ltd., New York, NY, pp 541-567 (1989) | |
| | NPL4 | CASON, J., <i>et al.</i> , "Analysis of human lymphocyte transformation responses to graded doses of T cell mitogens by curve fitting," <i>J. Immunol. Methods</i> 102:109-117, North-Holland Publishing Co. (1987) | |
| | NPL5 | CELIS, E., <i>et al.</i> , "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:2105-2109, National Academy of Sciences (1994) | |
| | NPL6 | CONSTANTIN, C.M., <i>et al.</i> , "Major Histocompatibility Complex (MHC) Tetramer Technology: An Evaluation," <i>Biol. Res. Nurs.</i> 4:115-127, Sage Publications, Inc. (October 2002) | |
| | NPL7 | DORNMAIR, K., <i>et al.</i> , "Structural Intermediates in the Reactions of Antigenic Peptides with MHC Molecules," <i>Cold Spring Harb. Symp. Quant. Biol.</i> 54:409-416, Cold Spring Harbor Laboratory Press (1989) | |
| | NPL8 | GELUK, A., <i>et al.</i> , "Identification of Major Epitopes of <i>Mycobacterium tuberculosis</i> AG85B That Are Recognized by HLA-A*0201-Restricted CD8 ⁺ T Cells in HLA-Transgenic Mice and Humans," <i>J. Immunol.</i> 165:6463-6471, The American Association of Immunologists (2000) | |
| | NPL9 | GERRITSMA, J.S.J., <i>et al.</i> , "The Constant Domain of IgG Is a Possible Target Antigen for Immunotherapy of B Cell Malignancies in HLA-A1 Mismatched Transplantation," <i>Blood</i> 98:404a-405a, The American Society of Hematology (December 2001) | |
| | NPL10 | GORGA, J.C., <i>et al.</i> , "Purification and Characterization of Class II Histocompatibility Antigens from a Homozygous Human B Cell Line," <i>J. Biol. Chem.</i> 262:16087-16094, The American Society for Biochemistry and Molecular Biology (1987) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 2 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|-----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL11 | HANSEN, T.H., and SACHS, D.H., "Chapter 16: The Major Histocompatibility Complex," in <i>Fundamental Immunology 2nd Ed.</i> , Paul, W.E., ed., Raven Press Publishing, New York, NY, pp 445-487 (1989) | |
| | NPL12 | HENDERSON, R.A., <i>et al.</i> , "Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:10275-10279, National Academy of Sciences (1993) | |
| | NPL13 | HENGEL, H., <i>et al.</i> , "Frequency of Herpes Simplex Virus-Specific Murine Cytotoxic T Lymphocyte Precursors in Mitogen- and Antigen-Driven Primary <i>in vitro</i> T Cell Responses," <i>J. Immunol.</i> 139:4196-4202, The American Association of Immunologists (1987) | |
| | NPL14 | HERR, W., <i>et al.</i> , "Detection and quantification of blood-derived CD8 ⁺ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens," <i>J. Immunol. Methods</i> 191:131-142, North-Holland Publishing Co. (1996) | |
| | NPL15 | HERR, W., <i>et al.</i> , "The use of computer-assisted video image analysis for the quantification of CD8 ⁺ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens," <i>J. Immunol. Methods</i> 203:141-152 North-Holland Publishing Co. (1997) | |
| | NPL16 | HICKLING, J.K., <i>et al.</i> , "Varicella-Zoster Virus-Specific Cytotoxic T Lymphocytes (Tc): Detection and Frequency Analysis of HLA Class I-Restricted Tc in Human Peripheral Blood," <i>J. Virol.</i> 61:3463-3469, American Society For Microbiology (1987) | |
| | NPL17 | HÖRIG, H., <i>et al.</i> , "An <i>in vitro</i> study of the dynamic features of the major histocompatibility complex class I complex relevant to its role as a versatile peptide-receptive molecule," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:13826-13831, National Academy of Sciences (1997) | |
| | NPL18 | HUGUES, S., <i>et al.</i> , "Generation and use of alternative multimers of peptide/MHC complexes," <i>J. Immunol. Methods</i> 268:83-92, North-Holland Publishing Co. (October 2002) | |
| | NPL19 | HUNKAPILLER, M.W., <i>et al.</i> , "Isolation of Microgram Quantities of Proteins from Polyacrylamide Gels for Amino Acid Sequence Analysis," <i>Methods Enzymol.</i> 91:227-236, Academic Press (1983) | |
| | NPL20 | KADIVAL, G.V., <i>et al.</i> , "Characterization of Serologic and Cell-Mediated Reactivity of a 38-kDa Antigen Isolated from <i>Mycobacterium tuberculosis</i> ," <i>J. Immunol.</i> 139:2447-2451, The American Association of Immunologists (1987) | |
| Examiner Signature | | | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 3 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL21 | KAWAKAMI, Y., <i>et al.</i> , "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:3515-3519, National Academy of Sciences (1994) | |
| | NPL22 | KAWAKAMI, Y., <i>et al.</i> , "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes," <i>J. Exp. Med.</i> 180:347-352, Rockefeller University Press (1994) | |
| | NPL23 | KUHNS, J.J., <i>et al.</i> , "Poor Binding of a HER-2/neu Epitope (GP2) to HLA-A2.1 Is Due to a Lack of Interactions with the Center of the Peptide," <i>J. Biol. Chem.</i> 274:36422-36427, The American Society for Biochemistry and Molecular Biology (1999) | |
| | NPL24 | MAEURER, M.J., <i>et al.</i> , "Improved Detection of Melanoma Antigen-Specific T Cells Expressing Low or High Levels of CD8 by HLA-A2 Tetramers Presenting a Melan-A/Mart-1 Peptide Analogue," <i>Int. J. Cancer</i> 97:64-71, Wiley-Liss, Inc. (January 2002) | |
| | NPL25 | MALE, D., "Chapter 2: Antibodies and Antigens," in <i>Immunology: An Illustrated Outline</i> , Bennet, D., ed., Gower Medical Publishing, London, England, p.19-34 (1986) | |
| | NPL26 | MARX, J.L., "Histocompatibility Restriction Explained," <i>Science</i> 235:843-844, American Association for the Advancement of Science (1987) | |
| | NPL27 | MEN, Y., <i>et al.</i> , "Assessment of Immunogenicity of Human Melan-A Peptide Analogues in HLA-A*0201/K ^b Transgenic Mice," <i>J. Immunol.</i> 162:3566-3573, The American Association of Immunologists (1999) | |
| | NPL28 | ROBINSON, M.A., and KINDT, T.J., "Chapter 17: Major Histocompatibility Complex Antigens and Genes," in <i>Fundamental Immunology 2nd Ed.</i> , Paul, W.E., ed., Raven Press Ltd., New York, NY, pp 489-539 (1989) | |
| | NPL29 | ROITT, I.M., <i>et al.</i> , eds., "Chapter 5: Antibody Structure and Function," in <i>Immunology</i> , Gower Medical Publishing, London, England, p.5.7, (1986) | |
| | NPL30 | RUPPERT, J., <i>et al.</i> , "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-937, Cell Press (1993) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 4 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL31 | SAMELSON, L.E., <i>et al.</i> , "T Cell Antigen Receptor Phosphorylation Induced by an Anti-Receptor Antibody," <i>J. Immunol.</i> 139:2708-2714, The American Association of Immunologists (1987) | |
| | NPL32 | SETTE, A., <i>et al.</i> , "Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells," <i>Nature</i> 328:395-399, Nature Publishing Group (1987) | |
| | NPL33 | SMITH, J.D., <i>et al.</i> , "Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous β_2 -microglobulin," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:7767-7771, National Academy of Sciences (1992) | |
| | NPL34 | SØRENSEN, A.L., <i>et al.</i> , "Purification and Characterization of a Low-Molecular-Mass T-Cell Antigen Secreted by <i>Mycobacterium tuberculosis</i> ," <i>Infect. Immun.</i> 63:1710-1717, American Society For Microbiology (1995) | |
| | NPL35 | Springfrog, "Temperature Converter," accessed online at http://springfrog.com/converter/temperature.htm , 2 pages (accessed 2008) | |
| | NPL36 | THORLEY-LAWSON, D.A., and ISRAELSOHN, E.S., "Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84:5384-5388, National Academy of Sciences (1987) | |
| | NPL37 | TSIEN, R.Y., <i>et al.</i> , "T-cell mitogens cause early changes in cytoplasmic free Ca ²⁺ and membrane potential in lymphocytes," <i>Nature</i> 295:68-71, Nature Publishing Group (1982) | |
| | NPL38 | TSOMIDES, T.J., <i>et al.</i> , "An optimal viral peptide recognized by CD8 ⁺ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88:11276-11280, National Academy of Sciences (1991) | |
| | NPL39 | TURNER, M.J., <i>et al.</i> , "Purification of Papain-solubilized Histocompatibility Antigens from a Cultured Human Lymphoblastoid Line, RPMI 4265," <i>J. Biol. Chem.</i> 250:4512-4519, American Society for Biochemistry and Molecular Biology (1975) | |
| | NPL40 | VALMORI, D., <i>et al.</i> , "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," <i>J. Immunol.</i> 161:6956-6962, The American Association of Immunologists (1998) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 5 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL41 | VAN DER BURG, S.H., <i>et al.</i> , "An HLA Class I Peptide-Binding Assay Based on Competition for Binding to Class I Molecules on Intact Human B Cells. Identification of Conserved HIV-1 Polymerase Peptides Binding to HLA-A*0301," <i>Hum. Immunol.</i> 44:189-198, Elsevier/North-Holland (1995) | |
| | NPL42 | VAN DER BURG, S.H., <i>et al.</i> , "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-3314, The American Association of Immunologists (1996) | |
| | NPL43 | "2006 Annual Immune Epitope Database and Discovery Workshop Meeting Report Executive Summary," at <i>The Third Annual Immune Epitope Database and Discovery Workshop</i> held on November 7 and 8, 2006 in North Bethesda, Maryland, 3 pages (January 2007) | |
| | NPL44 | ARNOLD, P.Y., <i>et al.</i> , "The Majority of Immunogenic Epitopes Generate CD4 ⁺ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues," <i>J. Immunol.</i> 169:739-749, The American Association of Immunologists (July 2002) | |
| | NPL45 | BELMARES, M.P., <i>et al.</i> , "Structural Factors Contributing to DM Susceptibility of MHC Class II/Peptide Complexes," <i>J. Immunol.</i> 169:5109-5117, The American Association of Immunologists (November 2002) | |
| | NPL46 | BERCOVICI, N., <i>et al.</i> , "New Methods for Assessing T-Cell Responses," <i>Clin. Diagn. Lab. Immunol.</i> 7:859-864, American Society for Microbiology (2000) | |
| | NPL47 | BODER, E.T., <i>et al.</i> , "Yeast Surface Display of a Noncovalent MHC Class II Heterodimer Complexed with Antigenic Peptide," <i>Biotechnol. Bioeng.</i> 92:485-491, Wiley (November 2005) | |
| | NPL48 | CALL, M.E., <i>et al.</i> , "Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum," <i>EMBO J.</i> 23:2348-2357, Oxford University Press (June 2004) | |
| | NPL49 | CALL, M.E., and Wucherpfennig, K.W., "The T Cell Receptor: Critical Role of the Membrane Environment in Receptor Assembly and Function," <i>Annu. Rev. Immunol.</i> 23:101-125, Annual Reviews (April 2005) | |
| | NPL50 | DUTOIT, V., <i>et al.</i> , "Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR," <i>J. Immunol.</i> 168:1167-1171, American Association of Immunologists (February 2002) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | FOSTER, Christine E. |
| Sheet | 6 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL51 | GRETEN, T.F., and SCHNECK, J.P., "Development and Use of Multimeric Major Histocompatibility Complex Molecules," <i>Clin. Diagn. Lab. Immunol.</i> 9:216-220, American Society for Microbiology (March 2002) | |
| | NPL52 | KLEIN, J., and SATO, A., "The HLA System - Second of Two Parts," <i>N. Engl. J. Med.</i> 343:782-786, Massachusetts Medical Society (September 2000) | |
| | NPL53 | MCMICHAEL, A.J., and KELLEHER, A., "The arrival of HLA class II tetramers," <i>J. Clin. Invest.</i> 104:1669-1670, American Society for Clinical Investigation (1999) | |
| | NPL54 | NEPOM, G.T., <i>et al.</i> , "HLA Class II Tetramers - Tools for Direct Analysis of Antigen-Specific CD4+ T Cells," <i>Arthritis Rheum.</i> 46:5-12, Wiley-Liss, Inc. (January 2002) | |
| | NPL55 | OGG, G.S., and MCMICHAEL, A.J., "HLA-peptide tetrameric complexes," <i>Curr. Opin. Immunol.</i> 10:393-396, Current Biology (1998) | |
| | NPL56 | REICHSTETTER, S., <i>et al.</i> , "Distinct T Cell Interactions with HLA Class II Tetramers Characterize a Spectrum of TCR Affinities in the Human Antigen-Specific T Cell Response," <i>J. Immunol.</i> 165:6994-6998, The American Association of Immunologists (December 2000) | |
| | NPL57 | RÖTZSCHKE, O., <i>et al.</i> , "Conformational variants of class II MHC/peptide complexes induced by N- and C-terminal extensions of minimal peptide epitopes," <i>Proc. Natl. Acad. Sci. USA</i> 96:7445-7450, National Academy of Sciences (1999) | |
| | NPL58 | SLIZ, P., <i>et al.</i> , "Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes," <i>J. Immunol.</i> 167:3276-3284, The American Association of Immunologists (September 2001) | |
| | NPL59 | STONE, J.D., <i>et al.</i> , "T-Cell Activation by Soluble MHC Oligomers Can Be Described by a Two-Parameter Binding Model," <i>Biophys. J.</i> 81:2547-2557, Biophysical Society (November 2001) | |
| | NPL60 | WELSH, R.M., "Assessing CD8 T Cell Number and Dysfunction in the Presence of Antigen," <i>J. Exp. Med.</i> 193:F19-F22, The Rockefeller University Press (March 2001) | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----------------------|----|---|--------------------------|--------------------------|
| Substitute for form 1449/PTO FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/684,268 |
| | | | | Filing Date | October 10, 2003 |
| | | | | First Named Inventor | MONTERO-JULIAN, Felix A. |
| | | | | Art Unit | 1641 |
| Examiner Name | FOSTER, Christine E. | | | | |
| Sheet | 7 | of | 7 | Attorney Docket Number | 2512.0230001/KWM/C-K |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published | T ² |
| | NPL61 | WOLL, M.M., <i>et al.</i> , "Direct Measurement of Peptide-Specific CD8+ T cells Using HLA-A2:Ig Dimer for Monitoring the <i>In Vivo</i> Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients," <i>J. Clin. Immunol.</i> 24:449-461, Kluwer Academic/Plenum Publishers (July 2004) | |
| | NPL62 | ZARUTSKIE, J.A., <i>et al.</i> , "A Conformational Change in the Human Major Histocompatibility Complex Protein HLA-DR1 Induced by Peptide Binding," <i>Biochemistry</i> 38:5878-5887, American Chemical Society (1999) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

826907v1

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.